EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieOpen Access · CC BY-NC 4.0

Epicardial ablation in high-risk Brugada syndrome to prevent ventricular fibrillation: results from a randomized clinical trial

Carlo Pappone iD, Giuseppe Ciconte iD, Gabriele Vicedomini, Emanuele Micaglio iD, Antonio Boccellino iD, Gabriele Negro iD, Luigi Giannelli iD, Roberto Rondine iD, Pasquale Creo iD, Adriana Tarantino iD, Marco Ballarotto, Vincenzo Maiolo iD und 7 weitere

Europace · 07.05.2025 · 27 (5)

DOI: 10.1093/europace/euaf097 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Europace, online erschienen am 22.05.2025. Verfasst von Carlo Pappone und 18 weiteren Autor:innen. Beteiligte Einrichtung: Arrhythmia and Electrophysiology Department, IRCCS Policlinico San Donato, Piazza E. Malan 1, San Donato Milanese, 20097 Milano, Italy. Hauptthemen laut MEDLINE: Ventricular Fibrillation, Brugada Syndrome, Catheter Ablation, Pericardium. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Italian Ministry of Health, IRCCS Policlinico San Donato.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aims

Epicardial ablation for Brugada syndrome (BrS) has shown promise in reducing ventricular fibrillation (VF), but its role remains controversial due to the lack of randomized trials. This study evaluates the efficacy of catheter ablation in high-risk BrS patients. Methods and results This prospective, single-centre, randomized (2:1) study enrolled BrS patients with cardiac arrest (CA) or appropriate ICD therapies. All patients had an ICD and were randomized to undergo epicardial ablation (ablation group) or no ablation (control group). Enrolment began in September 2017 and prematurely terminated in February 2024. The primary endpoint was freedom from VF recurrences. Secondary endpoints included procedure safety, ICD-related complications, and quality-of-life assessment. Forty patients (83% male, mean age 43.7 ± 12.1) were randomized: 26 in the ablation group and 14 in the control group. Thirty-six patients received appropriate ICD therapies before enrolment: 24 (92%) in the ablation group and 12 (86%) in the control group. One patient in the ablation group experienced a post-procedural pericardial effusion requiring pericardiocentesis. Thirteen patients (33%) had major ICD-related complications. After a mean follow-up of 4.0 ± 1.7 years, freedom from VF recurrence was 96% (25/26) in the ablation group and 50% (7/14) in the control group (P < 0.001). No unexplained or arrhythmic deaths occurred during follow-up.

Conclusion

Epicardial catheter ablation was associated with a reduction in VF recurrence compared with ICD therapy alone. These findings support the use of epicardial ablation in high-risk BrS patients. ClinicalTrials.gov ID NCT03294278

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Ventricular FibrillationBrugada SyndromeCatheter AblationPericardiumHumansMaleFemaleAdultMiddle AgedProspective StudiesRecurrenceDefibrillators, ImplantableTreatment OutcomeQuality of LifeRisk Factors

Stichwörter der Autor:innen

Arrhythmogenic substrateBrugada syndromeCardiac arrestEpicardiumICDVentricular fibrillation

Autor:innen und Institutionen

  • Arrhythmia and Electrophysiology Department, IRCCS Policlinico San Donato, Piazza E. Malan 1, San Donato Milanese, 20097 Milano, Italy.
  • School of Medicine, University Vita-Salute San Raffaele, Via Olgettina, 58, 20132 Milan, Italy.
  • Institute of Molecular and Translational Cardiology (IMTC), Piazza Malan 2, 20097, San Donato Milanese, Milan, Italy.

ORCID-Profile: Carlo Pappone, Giuseppe Ciconte, Emanuele Micaglio, Antonio Boccellino, Gabriele Negro, Luigi Giannelli, Roberto Rondine, Pasquale Creo, Adriana Tarantino, Vincenzo Maiolo, Roberto Manuello, Emanuela T Locati, Beniamino C Mazza, Žarko Ćalović, Luigi Anastasia

Förderung

  • Italian Ministry of Health
  • IRCCS Policlinico San Donato

Zitieren

APA

Pappone, C., Ciconte, G., Vicedomini, G., Micaglio, E., Boccellino, A., Negro, G., Giannelli, L., Rondine, R., Creo, P., Tarantino, A., Ballarotto, M., Maiolo, V., Ciaccio, C., Manuello, R., Locati, E. T., Mazza, B. C., Vecchi, M., Ćalović, Ž., & Anastasia, L. (2025). Epicardial ablation in high-risk Brugada syndrome to prevent ventricular fibrillation: results from a randomized clinical trial. Europace, 27(5). https://doi.org/10.1093/europace/euaf097

Vancouver

Pappone C, Ciconte G, Vicedomini G, Micaglio E, Boccellino A, Negro G, et al. Epicardial ablation in high-risk Brugada syndrome to prevent ventricular fibrillation: results from a randomized clinical trial. Europace. 2025;27(5). doi:10.1093/europace/euaf097

BibTeX
@article{Pappone2025,
  author = {Pappone, Carlo and Ciconte, Giuseppe and Vicedomini, Gabriele and Micaglio, Emanuele and Boccellino, Antonio and Negro, Gabriele and Giannelli, Luigi and Rondine, Roberto and Creo, Pasquale and Tarantino, Adriana and Ballarotto, Marco and Maiolo, Vincenzo and Ciaccio, Cristiano and Manuello, Roberto and Locati, Emanuela T and Mazza, Beniamino C and Vecchi, Mattia and Ćalović, Žarko and Anastasia, Luigi},
  title = {Epicardial ablation in high-risk Brugada syndrome to prevent ventricular fibrillation: results from a randomized clinical trial},
  journal = {Europace},
  year = {2025},
  volume = {27},
  number = {5},
  doi = {10.1093/europace/euaf097}
}
Kostenlos starten →